With vast experience spanning clinical research systems, healthcare analytics, and specialized sleep-medicine delivery, ...
Kirin Holdings management has avoided addressing significant questions on logic and viability of KV2027 “bridging” strategy LONDON--(BUSINESS WIRE)--Independent Franchise Partners, LLP (“Franchise ...
Sophia Willows stands at the nexus of technology and strategic management, her multifaceted roles illuminating her unique perspective. As a seasoned leader in software engineering based in New Zealand ...
(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL), a clinical-stage biopharmaceutical company, announced on Tuesday that it has received positive feedback from the U.S. Food and Drug Administration or ...
There are many hot conversations in biopharma today: market access, AI, transforming field operations. ClinicalMind’s Tom Sproat and 11Ten’s James Lewis discuss how leaders in biopharma can move these ...
Today, there are many factors threatening clinical workforce stability. Growing demands for healthcare services, ongoing provider shortages, and increasing burnout rates are making it hard to ensure ...
On Tuesday, Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced a positive response from the U.S. Food and Drug Administration (FDA) regarding its proposed in vitro bridging strategy for AD04. The FDA ...
Multicenter phase I/II study of abemaciclib and ramucirumab in metastatic gastroesophageal adenocarcinoma (GEA): CDK4/6 and cyclin D1 alterations as a predictor of response and survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results